Raymond T. Keane
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Nadim Ahmed | M | 56 | 3 Jahre | |
| Sandra Leung | F | 63 | 32 Jahre | |
| Stephen Webster | M | 63 | 4 Jahre | |
| Anne-Marie Martin | M | 52 | 2 Jahre | |
| Kimberly McCutcheon Jablonski | F | - | 21 Jahre | |
| Jeffrey Jones | M | 53 | 2 Jahre | |
| William Perhacs | M | - | 17 Jahre | |
| Tim Power | M | - | 18 Jahre | |
| Jay Smith | M | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 Jahre |
| Robert Kerrey | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Jay Skyler | M | 77 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Sunita Zalani | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 10 Jahre |
| Kevin Johnston | M | - | 2 Jahre | |
| Stephen Andre | M | 62 | 2 Jahre | |
| Patrick Hugh Conway | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
| Chad Messer | M | - | 2 Jahre | |
| Rose Weldon | F | - | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 Jahre | |
| Owen Hughes | M | 49 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 8 Jahre |
| Lamberto Andreotti | M | 73 | 19 Jahre | |
| James Cornelius | M | 81 | 10 Jahre | |
| Peter R. Dolan | M | 68 | 18 Jahre | |
| Maria E. Cantor | F | 56 | - | |
| Charles A. Heimbold | M | - | 20 Jahre | |
| James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 Jahre |
| Daniel M. Bollag | M | 63 | 11 Jahre | |
| Matthew Ros | M | 57 | 20 Jahre | |
| Mark W. Durand | M | 64 | 17 Jahre | |
| Brian Daniels | M | 65 | 14 Jahre | |
| David J. Helfgott | M | - | - | |
| John E. Elicker | M | 64 | 20 Jahre | |
| Togo Dennis West | M | 81 | 10 Jahre | |
| Gerald Bruce | M | 68 | 8 Jahre | |
| Priya Jambhekar | F | - | 3 Jahre | |
| Robert Whelan | M | 72 | 4 Jahre | |
| Steven B. Ratoff | M | 81 | 16 Jahre | |
| Massimo Radaelli | M | 65 | 8 Jahre | |
| Douglas Manion | M | 64 | 11 Jahre | |
| A. Collier Smyth | M | 78 | 15 Jahre | |
| Rosemary Crane | F | 64 | 20 Jahre | |
| Fouad Namouni | M | 55 | 21 Jahre | |
| Jon Wigginton | M | 62 | 2 Jahre | |
| Michael Williams | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 Jahre |
| Jason Haddock | M | 54 | 14 Jahre | |
| David Spellman | M | 48 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 Jahre |
| John Tsai | M | 57 | 11 Jahre | |
| Jeffrey Trigilio | M | 40 | 4 Jahre | |
| Joseph Squicciarino | M | 67 | 22 Jahre | |
| Wayne L. Wilson | M | 75 | 8 Jahre | |
| Lawrence Hamilton | M | 66 | 8 Jahre | |
| Charles Sigal | M | 72 | 16 Jahre | |
| Alan J. Lacy | M | 70 | 12 Jahre | |
| Louis Gerstner | M | - | - | |
| Laurie Glimcher | M | 72 | 20 Jahre | |
| Robert Williams | M | 75 | 7 Jahre | |
| Timothy Meeker | M | 77 | 13 Jahre | |
| Lewis B. Campbell | M | 77 | 18 Jahre | |
| Barry J. Wolfenson | M | 57 | 23 Jahre | |
| Leif Valdemar Johansson | M | 73 | 13 Jahre | |
| James Robinson | M | 88 | 29 Jahre | |
| Vicki Sato | M | 75 | 15 Jahre | |
| Laurie A. Allen | F | 63 | 9 Jahre | |
| Norbert Riedel | M | 66 | 6 Jahre | |
| Anthony Hooper | M | 69 | 15 Jahre | |
| Harrison Bains | M | 80 | 16 Jahre | |
| Louis J. Freeh | M | 74 | 8 Jahre | |
| Michael Grobstein | M | 81 | 13 Jahre | |
| William T. Comer | M | 85 | 9 Jahre | |
| Robert Berman | M | 61 | 10 Jahre | |
| Vladimir Coric | M | 53 | 8 Jahre | |
| Stacey Latuche | F | - | - | |
| John Shamsey | M | - | 6 Jahre | |
| Dolca Thomas | M | 53 | 4 Jahre | |
| Luisa Salter-Cid | M | 60 | 13 Jahre | |
| Robert E. Allen | M | - | 21 Jahre | |
| Dimitry Nuyten | M | 48 | 5 Jahre | |
| J. Brian Stalter | M | 52 | 11 Jahre | |
| Steve Innaimo | M | - | 23 Jahre | |
| Susan Sweeney | F | - | 24 Jahre | |
| Mark Neumann | M | 61 | 26 Jahre | |
| Marcel Giguère | M | - | 7 Jahre | |
| Catherine Knupp | M | 63 | 14 Jahre | |
| Donald Hayden | M | 68 | 25 Jahre | |
| Adeoye Olukotun | M | 79 | 13 Jahre | |
| R. Jean-Marc Sidney Huët | M | 55 | 1 Jahre | |
| Nancy Lurker | F | 66 | 14 Jahre | |
| Brian M. Gallagher | M | 76 | - | |
| Philippe Deschamps | M | 62 | 12 Jahre | |
| George Zavoico | M | - | - | |
| Dinesh Patel | M | 67 | 8 Jahre | |
| Charles Rowland | M | 65 | 8 Jahre | |
| John F. Bedard | M | 74 | - | |
| David J. Franklin | M | - | - | |
| Richard L. Wolgemuth | M | 78 | - | |
| Michael Loberg | M | 76 | 18 Jahre | |
| Carlo de Notaristefani | M | 67 | 7 Jahre | |
| Axel Hoos | M | 54 | 6 Jahre | |
| Michelle Werner | F | 48 | 10 Jahre | |
| Paul von Autenried | M | 62 | 26 Jahre | |
| Allison Luo | M | 50 | 8 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Raymond T. Keane
- Persönliches Netzwerk
